INSY stock forecast
Our latest prediction for INSYS Therapeutics, Inc.'s stock price was made on the Aug. 11, 2017 when the stock price was at 8.91$.
In the short term (2weeks), INSY's stock price should outperform the market by 4.20%. During that period the price should oscillate between -6.50% and +11.54%.
In the medium term (3months), INSY's stock price should outperform the market by 3.56%. During that period the price should oscillate between -14.79% and +27.36%.Get email alerts
About INSYS Therapeutics, Inc.
INSYS Therapeutics, Inc. operates as a pharmaceutical company, which develops and commercializes supportive care products. It focuses on utilizing commercial pharmaceutical products that include Subsys, a proprietary sublingual fentanyl spray for BTCP in opioid-tolerant adult patients; and Syndros, a proprietary orally administered liquid formulation of dronabinol for the treatment of CINV and anorexia associated with weight loss in patients with AIDS. The company was founded by John N. Kapoor on June 15, 1990 and is headquartered in Chandler, AZ.
At the moment the company generates 97M USD in revenues.
On its last earning announcement, the company reported a loss of -1.72$ per share.
The book value per share is 0.33$
Three months stock forecastAug. 11, 2017
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|